How many patients are switching to biosimilars?

That is a key question if long-run drug prices are going to come down for biologic products. We can decompose this question into 3 sub-questions: What share patients initiating therapy start on a biosimilar?What share of patients already using a biologic products switch to a biosimilar?Do patient of physician factors drive biosimilar prescribing patterns? A…

Read More